SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications

E Brown, HJL Heerspink, DJ Cuthbertson, JPH Wilding - The Lancet, 2021 - thelancet.com
SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art

MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …

Obesity phenotypes, diabetes, and cardiovascular diseases

ME Piché, A Tchernof, JP Després - Circulation research, 2020 - Am Heart Assoc
This review addresses the interplay between obesity, type 2 diabetes mellitus, and
cardiovascular diseases. It is proposed that obesity, generally defined by an excess of body …

The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)

DM Tanase, EM Gosav, CF Costea… - Journal of diabetes …, 2020 - Wiley Online Library
Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European …

JB Buse, DJ Wexler, A Tsapas, P Rossing… - Diabetes …, 2020 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, based …

An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors

T Salvatore, R Galiero, A Caturano, L Rinaldi… - International Journal of …, 2022 - mdpi.com
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …

2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of …

SR Das, BM Everett, KK Birtcher, JM Brown… - Journal of the American …, 2020 - jacc.org
2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk
Reduction in Patients With Type 2 Diabetes: A Report of the American College of …

The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management

B Xu, S Li, B Kang, J Zhou - Cardiovascular diabetology, 2022 - Springer
Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disease characterized by
chronic hyperglycemia causing from insufficient insulin signaling because of insulin …

Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

AJ Scheen - Nature reviews endocrinology, 2020 - nature.com
The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials

T Min, SC Bain - Diabetes Therapy, 2021 - Springer
Abstract Glucagon-like peptide 1 (GLP-1) based therapy is an established treatment option
for the management of type 2 diabetes mellitus (T2DM) and is recommended early in the …